埃克替尼与吉非替尼在一线治疗晚期EGFR阳性肺腺癌患者中的疗效分析

Effects of icotinib and gefitinib in first-line treatment of advanced lung adenocarcinoma patients with EGFR positive

目的分析一线应用埃克替尼和吉非替尼治疗晚期表皮生长因子受体（EGFR）阳性肺腺癌患者的疗效。方法回顾性分析120例口服埃克替尼或者吉非替尼治疗晚期EGFR阳性患者的临床资料，比较其治疗后2个月的近期疗效，以及其中位无进展生存期。结果吉非替尼组客观缓解率为11.1%，疾病控制率为17.9%；埃克替尼组客观缓解率为91.7%，疾病控制率为91.7%，两组客观缓解率和疾病控制率比较差异均未见统计学意义（P均〉0.05）。吉非替尼组中位无进展生存期（11.5个月）与埃克替尼组（11.2个月）比较差异未见统计学意义（P〉0.05）。结论埃克替尼一线治疗肺腺癌的疗效与吉非替尼无明显差异。

Objective To analyze the effects of icotinib and gefitinib in the fist-line treatment of patients with advanced epidermal growth factor receptor （EGFR） positive lung adenocarcinoma. Methods A retrospective study on clinical data of 120 patients who were diagnosed as EGFR positive lung adenocarcinoma and orally took icotinib or gefitinib for treatment was performed. Short-term effect （2 months after treatment） and median event progression-free survival were recorded and compared. Results In gefitinib group, the objective remission rate was 11.1%, and the disease control rate was 17. 9%; in icotinib group, the objective remission rate was 91.7%, and the disease control rate was 91.7%. There was no difference in objective remission rate and disease control rate between the two groups （P 〉 0. 05 ）. There was no significant difference in the median progress free survival between gefitinib group （ 11.5 months） and icotinib group （ 11.2 months）, P 〉 0. 05. Conclusions The efficacy of icotinib in the first-line treatment of lung adenocarcinoma is not significantly different from that of gefitinib.